Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
enmetazobactam 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| beta-lactamase inhibitors | 5809 | 1001404-83-6 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Enmetazobactam is a beta-lactamase inhibitor and it is the component of EXBLIFEP together with cefepime. Enmetazobactam inhibits certain Ambler class A beta-lactamases, including extended-spectrum beta-lactamases (ESBLs) and it protects cefepime from degradation by certain serine beta-lactamases such as ESBL.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
None
Predicted pharmacokinetic/toxicological properties (PK-AZ):
None
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Feb. 2, 2024 | FDA | Allecra Therapeutics | |
| March 21, 2024 | EMA | Advanz Pharma Limited |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| MeSH PA | D000890 | Anti-Infective Agents |
| MeSH PA | D000900 | Anti-Bacterial Agents |
| MeSH PA | D004791 | Enzyme Inhibitors |
| MeSH PA | D065093 | beta-Lactamase Inhibitors |
| CHEBI has role | CHEBI:33282 | antibacterial agent |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Complicated urinary tract infections | indication | 68566005 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
None
Orange Book patent data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
|---|---|---|---|---|---|---|---|---|---|---|
| EQ 2GM BASE/VIAL;0.5GM/VIAL | EXBLIFEP | ORCHID PHARMA | N216165 | Feb. 22, 2024 | DISCN | POWDER | INTRAVENOUS | 7687488 | Dec. 3, 2027 | USE OF EXBLIFEP (CEFEPIME AND ENMETAZOBACTAM) FOR TREATING COMPLICATED URINARY TRACT INFECTIONS (CUTI) INCLUDING PYELONEPHRITIS CAUSED BY DESIGNATED SUSCEPTIBLE MICROORGANISMS |
| EQ 2GM BASE/VIAL;0.5GM/VIAL | EXBLIFEP | ORCHID PHARMA | N216165 | Feb. 22, 2024 | DISCN | POWDER | INTRAVENOUS | 11124526 | Nov. 7, 2034 | USE OF SPECIFIED POLYMORPHS OF EXBLIFEP (CEFEPIME AND ENMETAZOBACTAM) FOR TREATING COMPLICATED URINARY TRACT INFECTIONS (CUTI) INCLUDING PYELONEPHRITIS CAUSED BY DESIGNATED SUSCEPTIBLE MICROORGANISMS |
Orange Book exclusivity data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
|---|---|---|---|---|---|---|---|---|---|
| EQ 2GM BASE/VIAL;0.5GM/VIAL | EXBLIFEP | ORCHID PHARMA | N216165 | Feb. 22, 2024 | DISCN | POWDER | INTRAVENOUS | Feb. 22, 2029 | NEW CHEMICAL ENTITY |
| EQ 2GM BASE/VIAL;0.5GM/VIAL | EXBLIFEP | ORCHID PHARMA | N216165 | Feb. 22, 2024 | DISCN | POWDER | INTRAVENOUS | Feb. 22, 2034 | GENERATING ANTIBIOTIC INCENTIVES NOW |
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Beta-lactamase | Enzyme | INHIBITOR | UNKNOWN | DRUG LABEL |
External reference:
| ID | Source |
|---|---|
| CHEMBL4458276 | ChEMBL_ID |
| C000656730 | MESH_SUPPLEMENTAL_RECORD_UI |
| C5392310 | UMLSCUI |
| CHEBI:757682 | CHEBI |
| CHEMBL1200962 | ChEMBL_ID |
| 10913 | INN_ID |
| 23653540 | PUBCHEM_CID |
| 42650 | MMSL |
| d10169 | MMSL |
| 019670 | NDDF |
| 12188 | IUPHAR_LIGAND_ID |
| 80VUN7L00C | UNII |
| 2675985 | RXNORM |
| C000729273 | MESH_SUPPLEMENTAL_RECORD_UI |
| D12817 | KEGG_DRUG |
Pharmaceutical products:
None